Preferred Label : isatuximab;

CISMeF synonym : SAR650984;

MeSH hyponym : SAR6 50984;

Related MeSH term : isatuximab-irfc;

UNII : R30772KCU0;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-marr/isatuximab
2025
false
false
false
France
French
risk management
isatuximab
guideline
patient education handout
blood transfusion
indirect coombs test
Laboratory test interference

---
https://www.has-sante.fr/jcms/p_3554633/fr/sarclisa-isatuximab-myelome-multiple
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Bortezomib/Dexamethasone/Isatuximab/Lenalidomide Regimen
adult
infusions, intravenous
Antineoplastic Agents, Immunological
isatuximab
evaluation of the transparency committee
multiple myeloma
isatuximab

---
https://ansm.sante.fr/tableau-acces-derogatoire/sarclisa
2024
false
false
false
France
French
drug information
infusions, intravenous
isatuximab
antineoplastic combined chemotherapy protocols
multiple myeloma
Bortezomib/Dexamethasone/Isatuximab/Lenalidomide Regimen

---
https://www.has-sante.fr/jcms/p_3223297/fr/sarclisa
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
isatuximab
adult
antineoplastic combined chemotherapy protocols
multiple myeloma
Dexamethasone/Isatuximab/Pomalidomide Regimen
dexamethasone
pomalidomide
Refractory Multiple Myeloma
Recurrent Multiple Myeloma
isatuximab
isatuximab
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal
thalidomide
thalidomide
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
https://www.has-sante.fr/jcms/p_3299691/fr/sarclisa-isatuximab-myelome-multiple
2021
false
false
false
France
evaluation of the transparency committee
Myeloma
indicators and reagents
multiple myeloma
Sarclisa
indication of
indicators
traction
Myeloma
isatuximab
multiple myeloma
isatuximab

---
https://www.ema.europa.eu/en/medicines/human/EPAR/sarclisa
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
orphan drug production
antineoplastic combined chemotherapy protocols
pomalidomide
dexamethasone
antineoplastic agents
antineoplastic agents
multiple myeloma
adult
infusions, intravenous
CD38 protein, human
product surveillance, postmarketing
recurrence
aged
pregnancy
breast feeding
isatuximab
survival analysis
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Dexamethasone/Isatuximab/Pomalidomide Regimen
isatuximab
isatuximab
antibodies, monoclonal
antibodies, monoclonal
thalidomide
thalidomide
membrane glycoproteins
ADP-ribosyl Cyclase 1
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
Nous contacter.
03/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.